A5100388711- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal and Anal Carcinomas
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Cancer Research and Treatments
- Cardiac tumors and thrombi
- Cancer-related molecular mechanisms research
- Prostate Cancer Treatment and Research
- RNA modifications and cancer
- Congenital Diaphragmatic Hernia Studies
- Cancer, Hypoxia, and Metabolism
- Metastasis and carcinoma case studies
- Vascular Tumors and Angiosarcomas
- Bone Tumor Diagnosis and Treatments
- Prostate Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
Second Hospital of Shandong University
2024-2025
University of Electronic Science and Technology of China
2021-2025
Affiliated Eye Hospital of Wenzhou Medical College
2024
Wenzhou Medical University
2011-2024
Wuhan Sixth Hospital
2024
Guiyang Medical University
2023-2024
Clemson University
2021-2023
Sichuan University
2023
West China Hospital of Sichuan University
2023
Tongji Hospital
2022-2023
Background: Although growth advantage of certain clones would ultimately translate into a clinically visible disease progression, radiological imaging does not reflect clonal evolution at molecular level. Circulating tumor DNA (ctDNA), validated as tool for mutation detection in lung cancer, could dynamic changes. We evaluated the utility ctDNA predictive and prognostic marker monitoring advanced non-small cell cancer (NSCLC) patients. Methods: This is multicenter prospective cohort study....
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have a significant therapeutic effect in the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. However, acquired resistance greatly limits survival benefit EGFR-TKIs for EGFR-mutant NSCLC patients. We aimed to assess efficacy and safety stereotactic body radiotherapy (SBRT) plus these patients.In this prospective, randomized, controlled, phase 2 study, participants were recruited from 4...
Background: The outbreak of coronavirus disease 2019 (COVID-19) has led to a large and increasing number patients requiring prolonged mechanical ventilation tracheostomy. indication optimal timing tracheostomy in COVID-19 are still unclear, the outcomes about have not been extensively reported. We aimed describe clinical characteristics with confirmed severe acute respiratory syndrome 2 (SARS-CoV-2) pneumonia who underwent elective tracheostomies. Methods: multi-center, retrospective,...
Abstract Purpose: To explore the efficacy and safety of TQB2450 combined with anlotinib in patients locally advanced or metastatic soft-tissue sarcoma (LA/M STS). Patients Methods: This was a single arm phase II study (TQB2450-Ib-02 study) performed at two hospitals China to assess potency LA/M STS. were previously unresponsive least one chemotherapy regimen. Anlotinib (12 mg every day) administered orally from day 1 14 3 weeks. by intravenous infusion 1,200 on The primary endpoint objective...
Background: Liver cancer, specifically hepatocellular carcinoma (LIHC), ranks as the second most common cause of cancer-related fatalities globally. Moreover, occurrence rate LIHC is steadily increasing. A recently identified gene, SPSB2, has been implicated in cell signaling, impacting development and progression non-small lung cancer. Nevertheless, studies on role SPSB2 pathogenesis are lacking. Methods: Using TCGA, GTEx, GEO databases, we obtained differentially expressed genes that...
Heterozygous deletion of chromosome 17p (17p) is one the most frequent genomic events in human cancers. Beyond tumor suppressor TP53, POLR2A gene encoding catalytic subunit RNA polymerase II (RNAP2) also included a ~20-megabase region 63% metastatic castration-resistant prostate cancer (CRPC). Using focused CRISPR-Cas9 screen, we discovered that heterozygous loss confers selective dependence CRPC cells on ubiquitin E3 ligase Ring-Box 1 (RBX1). RBX1 activates by K63-linked ubiquitination and...
Purpose: Responses to EGFR -targeted therapy are generally temporary, due inevitable drug resistance. The prevalence and characteristics of receptortyrosine–kinase (RTK) fusion as acquired resistance tyrosine–kinase inhibitors (TKIs) rarely investigated. Methods: We retrospectively reviewed genomic profiling data 3873 (exons 18–21)-mutant lung cancer patients with more than once next-generation sequencing detection. A total 16 who RTK fusions during EGFR-TKI treatment paired pre-...
ROS1 rearrangements define a distinct molecular subset of non-small-cell lung cancer (NSCLC), which can be treated effectively with crizotinib, tyrosine kinase inhibitor (TKI) targeting ROS1/MET/ALK rearrangements. Diverse efficacy was observed in -rearranged NSCLC patients. Because its rareness, very limited studies have investigated the correlation between different fusion partners and response to crizotinib. In this study, we retrospectively screened 6,235 advanced patients (stage IIIB...
Background Early onset colorectal cancer (EOCRC) is a heterogeneous subtype with obvious hereditary tendencies and increasing incidence. We sought to determine the susceptibility genes molecular characteristics of EOCRC. Methods 330 EO metastatic CRC (mCRC) (≤55 years) 110 average-onset (AO) mCRC patients (>55 were enrolled. Capture-based targeted sequencing was performed on tumor tissue paired white blood cells using panel 520 genes. The association between alterations overall survival (OS)...
The goal of this study was to retrospectively analyze the efficacy and safety pembrolizumab in real-world treatment soft tissue sarcoma (STS).We analyzed 38 patients who suffered from STS received July 2017 December 2018 our hospital. We investigated influence clinical characteristics, timing, protocol on objective response rate (ORR). also factors affecting overall survival (OS) progression-free (PFS), as well occurrence severe adverse events (SAEs).The ORR 19.4% (7/36). ORRs first-line,...
Pulmonary enteric adenocarcinoma (PEAC) is a rare subtype of pulmonary that lacks effective treatment. The purpose this research was to investigate the clinical characteristics, treatment, and prognosis PEAC, as well impact relevant factors on survival, thus providing reference for management patients with disease.For study, we gathered data from 26 PEAC in Affiliated Cancer Hospital Zhengzhou University June 2014 2021. We used SEER*Stat software V8.3.5 download Surveillance, Epidemiology,...
Currently, in clinical settings, all TP53 mutations have been considered equally. However, numerous studies demonstrated that the position and type of mutation differential effects on prognosis. Such discrepancy can be partially due to lack unifying classification system for mutations. In present study, two most frequently used systems were compared, according location or its functional p53 protein impact overall survival (OS) time 379 Chinese patients with advanced lung cancer was analyzed....
Abstract Background Early metastasis is a hallmark of osteosarcoma (OS), highly common type malignant tumor. Members the potassium inwardly rectifying channel family exert oncogenic effects in various cancers. However, role subfamily J member 2 (KCNJ2) OS unclear. Methods The expression KCNJ2 tissues and cell lines was measured using bioinformatic analysis, immunohistochemistry, western blotting. Wound-healing assays, Transwell lung models were used to analyze on mobility cells. molecular...
Purpose:EGFR and anaplastic lymphoma kinase (ALK) alterations have been regarded as oncogenic drivers incorporated into clinical practices to manage nonsmall cell lung cancer (NSCLC). Alterations of these two genes were traditionally considered be mutually exclusive, but recent studies suggested that they can occur concomitantly. Here, we investigated the prevalence, features outcomes in response treatment NSCLC patients who harbor EGFR ALK co-alterations. Methods: We reviewed genomic...